Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

14.31 -6.84

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

14.8

Max

15.7

Belangrijke statistieken
By Trading Economics
Inkomsten	-4.3M -18M
EPS	-0.19
Werknemers	37
EBITDA	-5.3M -17M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+98.92% upside

Dividenden
By Acuity
Volgende Winsten	3 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	130M 1.3B
Vorige openingsprijs	21.15
Vorige sluitingsprijs	14.31

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 aug 2026, 23:56 UTC

News

Wayfair shares rise in after-market hours after Rosenblatt analyst Scott Devitt initiated coverage with a Buy rating and a price target of $125.00.

19 aug 2026, 23:56 UTC

Peloton Interactive Inc shares are lower in after-market hours with no specific news to explain the decline. The stock remains below its 20-day moving average.

19 aug 2026, 23:56 UTC

Shares of Nova Ltd. rose in after-market trading, despite earlier fluctuations and remaining below its 20-day moving average.

19 aug 2026, 23:56 UTC

Certara Inc. shares are lower in after-hours trading, showing slight declines since Wednesday's close while remaining above the 20-day moving average.

19 aug 2026, 23:56 UTC

CareDx Inc shares are higher in after-market hours, remaining above their 20-day moving average. No specific news was identified to explain the movement.

19 aug 2026, 23:56 UTC

Correlated Moves

Pinnacle West Capital shares are modestly higher in after-market trading, tracking a similar rise in PG&E Corp, indicating potential market correlation.

19 aug 2026, 23:56 UTC

Pentair PLC shares are lower in after-market trading, reflecting routine activity and slight declines since Wednesday's close. The price remains near the one-month midpoint.

19 aug 2026, 23:56 UTC

Best Buy Co Inc shares are higher in after-market trading, fluctuating slightly while remaining above their 20-day moving average. No specific news was identified.

19 aug 2026, 23:56 UTC

Charles River Laboratories shares are higher in after-market trading, reaching a notable increase since Wednesday's close and positioning near the upper end of its one-month range.

19 aug 2026, 23:56 UTC

Quest Diagnostics Inc shares are higher in after-market hours, continuing a trend of four consecutive sessions finishing above their 20-day moving average.

19 aug 2026, 23:56 UTC

GSI Technology Inc's shares are higher in after-market trading, despite a recent decline and ongoing weakness below the 20-day moving average.

19 aug 2026, 23:56 UTC

Invesco DB Agriculture Fund is higher in after-market trading, reflecting a notable upward move since Wednesday's close and trading near its one-month range.

19 aug 2026, 23:56 UTC

CF Industries remains roughly flat in after-market hours, trading near the middle of its one-month range and slightly below its 20-day moving average.

19 aug 2026, 23:56 UTC

Apollo Global Management shares are trading lower in after-market hours. No specific company news was identified to explain this movement.

19 aug 2026, 23:56 UTC

Ares Capital Corp shares are higher in after-market trading, reflecting a generally positive performance backdrop. The stock remains above its 20-day moving average.

19 aug 2026, 23:56 UTC

Huntington Bancshares Inc shares are higher in after-market trading, despite no specific news. The stock remains below its 20-day moving average.

19 aug 2026, 23:56 UTC

FactSet Research Systems is trading lower in after-market hours, reflecting a decline since Wednesday's close, with no specific news identified for the movement.

19 aug 2026, 23:56 UTC

Shoals Technologies Group Inc is trading lower in after-market hours, continuing a downward trend without any specific news to explain the movement.

19 aug 2026, 23:56 UTC

News

Social Media

Cogent Communications is facing a class action lawsuit over alleged false statements, contributing to a decline in shares during after-market hours.

19 aug 2026, 23:52 UTC

News

Correlated Moves

Cohen & Steers Inc. shares are lower in after-market trading, continuing a trend of five consecutive daily declines. The fund declared a monthly dividend of $0.126 per share.

19 aug 2026, 23:52 UTC

Progressive Corp shares are higher in after-market hours, reflecting a modest gain since Wednesday's close. The stock remains above its 20-day moving average.

19 aug 2026, 23:51 UTC

Doximity Inc shares are lower in after-market trading, with no specific news identified for the decline. The stock remains above its 20-day moving average.

19 aug 2026, 23:51 UTC

Peabody Energy shares are lower in after-market trading, reversing an earlier gain. The stock remains above its 20-day moving average.

19 aug 2026, 23:51 UTC

Patria Investments Ltd is trading higher in after-market hours, reaching 2.45% above Wednesday's close and showing strong momentum above its 20-day moving average.

19 aug 2026, 23:51 UTC

Workday Inc. shares are higher in after-market trading, continuing a month-long upward trend and remaining above the 20-day moving average.

19 aug 2026, 23:51 UTC

Pinterest Inc. shares moved lower in after-market trading, retracing earlier gains and remaining below their 20-day moving average.

19 aug 2026, 23:51 UTC

Kilroy Realty Corp shares are lower in after-market trading, continuing a decline since Wednesday's close and positioned below its 20-day moving average.

19 aug 2026, 23:51 UTC

Take-Two Interactive shares are higher in after-market hours, recovering from earlier lows. No specific news was identified to explain the price movement.

19 aug 2026, 23:51 UTC

News

Biomarin Pharmaceutical Inc shares are lower in after-market hours amid a broader Biotechnology sector decline, despite a recent $275 million acquisition of Alesta Therapeutics.

19 aug 2026, 23:51 UTC

Mixed trading in European equities as Eurozone inflation rises to 2.9% and German Bund yields hit a 12-year high amid geopolitical tensions.

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

98.92% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 29.5 USD 98.92%

Hoogste 33 USD

Laagste 27 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.